To elucidate the mechanism behind the superior tumor control observed in the RT and SIRPα blockade combination, we used flow cytometry to measure SIRPα, CD209, and HLA-DR expression in tumor tissues from the xenograft models. This evidence concerns the gene SIRPA and neoplasm.